Where Ceramides (plasma) is reported
Also listed as: Ceramides; Sphingolipids; Sphingolipids — LC overlap
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Long COVID | ↓ reduced | recovered individuals without persistent symptoms (fully recovered) | Mitochondrial dysfunction, membrane integrity | Pérez-Mazliah et al. 2024 |
| ME/CFS | ↓ reduced | healthy controls | Mitochondrial dysfunction | Saito et al. 2024 |
Frequently asked questions
In which conditions is Ceramides (plasma) altered?
In the OSMF atlas Ceramides (plasma) is reported in Long COVID, ME/CFS. It is reduced in 2 across 2 entries.
Does Ceramides (plasma) point to one specific diagnosis?
No. Because Ceramides (plasma) changes in several conditions (Long COVID, ME/CFS), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
Is there a standard clinical test for Ceramides (plasma)?
The atlas entries for Ceramides (plasma) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal Ceramides (plasma) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.